Pages that link to "Q38601785"
Jump to navigation
Jump to search
The following pages link to Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (Q38601785):
Displaying 50 items.
- Potential efficacy of interleukin-1β inhibition in lung cancer (Q40074198) (← links)
- The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology (Q45069046) (← links)
- Can Biomarkers Advance HIV Research and Care in the ART Era? (Q46442340) (← links)
- Angiogenesis, Cancer, and Vascular Aging. (Q46716639) (← links)
- Redundancy and robustness versus division of labour and specialization in innate immunity (Q47259971) (← links)
- Overview of the IL-1 family in innate inflammation and acquired immunity (Q47285878) (← links)
- Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth (Q47390109) (← links)
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial (Q47394886) (← links)
- Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond (Q47599422) (← links)
- Canakinumab for secondary prevention of atherosclerotic disease (Q47770079) (← links)
- A new lead to NLRP3 inhibition (Q48143558) (← links)
- The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired. (Q49167115) (← links)
- The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. (Q49993738) (← links)
- Heart transplantation at 50. (Q50060315) (← links)
- Inflammation in 2017: Connectivity to other fields brings new ideas (Q50093287) (← links)
- Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer (Q50107745) (← links)
- A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? (Q50125894) (← links)
- Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility (Q50168209) (← links)
- Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials (Q50185854) (← links)
- The year in cardiology 2017: prevention (Q50193445) (← links)
- Cardiorespiratory fitness and the metabolic syndrome: Roles of inflammation and abdominal obesity (Q51758821) (← links)
- Understanding the tumor immune microenvironment (TIME) for effective therapy. (Q52311744) (← links)
- Chlamydia and Lipids Engage a Common Signaling Pathway That Promotes Atherogenesis. (Q52330706) (← links)
- Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. (Q52573372) (← links)
- Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism. (Q52592593) (← links)
- Ajulemic acid: potential treatment for chronic inflammation. (Q52594380) (← links)
- IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis. (Q52612756) (← links)
- A20/Tumor Necrosis Factor α-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models. (Q52668335) (← links)
- Targeting interleukin-22 for cancer therapy. (Q52721732) (← links)
- Autoinflammatory Disease in the Lung. (Q52801814) (← links)
- IL-1 and IL-1 regulatory pathways in cancer progression and therapy. (Q53179726) (← links)
- Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. (Q54260312) (← links)
- Tnfrsf12a-Mediated Atherosclerosis Signaling and Inflammatory Response as a Common Protection Mechanism of Shuxuening Injection Against Both Myocardial and Cerebral Ischemia-Reperfusion Injuries. (Q54974896) (← links)
- Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. (Q55175882) (← links)
- Can we use interleukin-1β blockade for lung cancer treatment? (Q55214517) (← links)
- Atherosclerosis as an inflammatory disease: Doubts? No more. (Q55323797) (← links)
- Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. (Q55331774) (← links)
- Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. (Q55396890) (← links)
- Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. (Q55424979) (← links)
- Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis. (Q55668764) (← links)
- Molecular mechanisms of the preventable causes of cancer in the United States (Q56475873) (← links)
- Innate and adaptive immunity in atherosclerosis (Q56961974) (← links)
- Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy (Q57116991) (← links)
- Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition (Q57162899) (← links)
- The Future of IL-1 Targeting in Kidney Disease (Q57177982) (← links)
- Application of a novel nanoemulsion adjuvant for rabies vaccine which stabilizes a Krebs cycle intermediate (SDH) in an animal model (Q57288834) (← links)
- Growth differentiation factor-15 reveals the dark side of heart failure (Q57453140) (← links)
- Can heart failure cause cancer? (Q57464849) (← links)
- Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) (Q57495847) (← links)
- Age-Related Adverse Inflammatory and Metabolic Changes Begin Early in Adulthood (Q57598933) (← links)